Sigilon Therapeutics Appoints Sarah Yuan, Ph.D., as Chief Technical Operations Officer
February 22, 2022 16:30 ET
|
Sigilon Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its...
Sigilon Therapeutics to Present Preclinical Data at the 18th Annual WORLDSymposium™ on Lysosomal Diseases, MPS-1 and MPS-6
January 31, 2022 07:00 ET
|
Sigilon Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its...
Sigilon Therapeutics Announces Strategic Reprioritization
December 13, 2021 17:00 ET
|
Sigilon Therapeutics, Inc.
- Company plans to prioritize MPS-1 and diabetes with continued focus on platform optimization – - Workforce reduction of approximately 38% – - Anticipated cash runway extended into 2024 – ...
Sigilon Therapeutics Announces Update on SIG-001 Phase 1/2 Study in Hemophilia A
November 29, 2021 07:00 ET
|
Sigilon Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded...
Sigilon Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
November 10, 2021 16:15 ET
|
Sigilon Therapeutics, Inc.
Company expects to complete its investigation of the clinical hold on its Phase 1/2 trial of SIG-001 in hemophilia A by year-end On track to initiate a Phase 1/2 trial of SIG-005 for MPS-1...
Sigilon Therapeutics to Participate in the Jefferies London Healthcare Conference
November 09, 2021 07:00 ET
|
Sigilon Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded...
Sigilon Therapeutics Announces Acceptance of Clinical Trial Application in the UK for SIG-005 for the Treatment of Mucopolysaccharidosis Type I
September 09, 2021 07:00 ET
|
Sigilon Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its...
Sigilon Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
September 02, 2021 07:00 ET
|
Sigilon Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its...
Sigilon Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights
August 10, 2021 07:00 ET
|
Sigilon Therapeutics, Inc.
CAMBRIDGE, Ma., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded...
Sigilon Therapeutics Presents Preclinical Data at the 16th International Symposium on MPS and Related Diseases
July 23, 2021 07:00 ET
|
Sigilon Therapeutics, Inc.
CAMBRIDGE, Mass., July 23, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded...